I'll answer you in English, if I may, because I need to use technical terms.
Whenever competitors come to us in investigations, we are skeptical. We look at the evidence. We look at the underlying documents. We look at the incentives and the ability to compete. We have a degree of skepticism when we are dealing with incumbent competitors in the marketplace. What drives our decision-making is the totality of the evidence that we look at in our investigation.
In this particular case, we thought that led to a substantial lessening of competition emanating from the Rogers-Shaw transaction, as mentioned in my opening statement. Our concern was not with Videotron. Our concern was with the assets that Videotron will have to compete as opposed to what Shaw had to compete previously. Under our remedies bulletin, we just did not think those assets were sufficient to address the substantial lessening of competition caused by Shaw's exit.